General Discussions

Click here to start a new discussion.

ASCO Offers Resources for You and Your Patients

Lisa Schulmeister, RN, MN, APRN-BC, OCN®, FAAN Editor-in-Chief OncLive Nursing Oncology Nursing Consultant, Adjunct Assistant Professor of Nursing Louisiana State Health Sc...

2 replies - Jan 26, 2021 11:17:49 am
Discussions - General Discussions

Nurses Have Key Role in Managing Side Effects of Maintenance Therapy

Susan J. Keen, RN, OCN Deborah L. Selm-Orr, RN, MS, CRNP, AOCN What is the value of maintenance therapy in patients with lung or breast cancers, and how and when should it be used? ...

4 replies - Jan 23, 2021 4:18:41 pm
Discussions - General Discussions

Colleen Jennings on Improving Follow-Up Phone Calls

Colleen Jennings, RN, BSN, HN-BC, of Cancer Treatment Centers of America at Eastern Regional Medical Center, discusses the initiative their center took to improve discharge follow-up calls. The ...

22 replies - Jan 23, 2021 4:14:00 pm
Discussions - General Discussions

Promoting Sleep in Children With Cancer

Rebecca Kronk, PhD, CRNP, MSN Assistant Professor, Duquesne University School of Nursing Over the past decade, evidence has mounted recognizing sleep disturbances an...

3 replies - Jan 22, 2021 7:40:37 am
Discussions - General Discussions

Knowing the Signs: Recognizing Depression in African Americans With Cancer

Amy Zhang, PhD A new study has found that African American patients with cancer feel and describe depression differently than their Caucasian counterparts. Findings from a pilot study, pos...

2 replies - Jan 20, 2021 7:22:01 am
Discussions - General Discussions

Treatment of Depression and Fatigue in Cancer Survivors Needs Improvement

Cancer and its treatments can bring a number of adverse events (AEs), and as more patients are living longer after their treatment, these effects can become long-lasting. Often, oncology nurses are...

1 replies - Jan 20, 2021 7:21:20 am
Discussions - General Discussions

FDA Approves Crizotinib for Pediatric/Young Adult ALK+ Anaplastic Large Cell Lymphoma

The FDA has approved crizotinib (Xalkori) for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large c...

4 replies - Jan 19, 2021 6:38:58 am
Discussions - General Discussions

More Targets Discovered, More Molecular Testing Needed in Lung Cancer

Molecular testing is a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1...

9 replies - Jan 10, 2021 1:42:42 pm
Discussions - General Discussions

Next Page >>